RETRACTED ARTICLE: Aminophylline and caffeine for reversal of adverse symptoms associated with regadenoson SPECT MPI
- 29 March 2016
- journal article
- retraction
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 24 (3) , 1062-1070
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Safety of Regadenoson in Patients with End-Stage Renal DiseaseThe American Journal of Cardiology, 2010
- Effects of Age, Gender, Obesity, and Diabetes on the Efficacy and Safety of the Selective A2A Agonist Regadenoson Versus Adenosine in Myocardial Perfusion ImagingJACC: Cardiovascular Imaging, 2008
- Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: Results of the ADVANCE phase 3 multicenter international trialJournal of Nuclear Cardiology, 2007
- Regadenoson Pharmacokinetics and Tolerability in Subjects With Impaired Renal FunctionThe Journal of Clinical Pharmacology, 2007
- “One” Cup of Coffee and Nuclear SPECT to GoJACC, 2007
- Stress protocols and tracersJournal of Nuclear Cardiology, 2006
- Coffee and Health: A Review of Recent Human ResearchCritical Reviews in Food Science and Nutrition, 2006
- Comparative Profile of Vasodilation by CVT-3146, a Novel A2A Receptor Agonist, and Adenosine in Conscious DogsThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Pharmacologic Stress ImagingJAMA, 1991
- Inhibition of Coronary Vasodilating Action of Dipyridamole and Adenosine by Aminophylline in the DogCirculation Research, 1970